



Department of Health Care Finance



PHARMACY & THERAPEUTICS COMMITTEE MEETING
AGENDA

December 5th, 2024

Time: 2:30 PM – 5:30 PM

Online only

Please register at

https://primetherapeutics.zoom.us/webinar/register/WN_o72Ar8jMS0Cy7nTxFGj-SQ

- 1) Call to Order Charlene Fairfax, RPh
- 2) Minutes of Previous Meeting Charlene Fairfax, RPh
- 3) Comments from Interested Parties * Gidey Amare, PharmD, MS
- 4) Clinical Drug Class Reviews Zakia Al-Amin, PharmD, RPh, BCACP
Ronald E. Kavanagh, BSP Pharm, PharmD, PhD, RPh

| | |
|--|-------------------------------------|
| Angiotensin Modulator Combinations | Hemophilia Agents |
| Angiotensin Modulators | Hepatitis B Agents |
| Antianginal Agents (Ranexa) | Hepatitis C Agents |
| Antibiotics, Topical | HIV and AIDS Treatments |
| Anticoagulants | Immunomodulators, Atopic Dermatitis |
| Antihypertensives, Sympatholytics | Immunomodulators, Topical |
| Antipsoriatics, Oral | Lipotropics, Others |
| Antipsoriatics, Topical | Lipotropics, Statins |
| Antiviral Agents, Oral (HSV & Influenza) | Methotrexate |
| Antiviral Agents, Topical | Platelet Aggregation Inhibitors |
| Beta-Blockers | Rosacea Agents, Topical |
| Bile Salts | Sickle Cell Anemia Agents |
| Calcium Channel Blockers | |
- 5) Executive Session (Committee Only) ** Charlene Fairfax, RPh
MMA Representatives
- 6) Final Recommendations of Preferred Drugs *** MMA Representatives
- 7) Announcement of Next Scheduled P&T Committee Meeting Charlene Fairfax, RPh
Thursday March 6th, 2025
- 8) Final Comments and Adjournment Charlene Fairfax, RPh

* Individuals wishing to make oral presentations to the Committee will be limited to three (3) minutes

** Closed Session

*** Open Session